TPG buying Par Pharmaceuticals

Investment firm TPG will acquire generics company Par Pharmaceutical Cos. Inc. (NYSE:PRX) for $50 per share in cash, or about $1.9 billion. The price is a 37% premium to Par's close of $36.58 on Friday, before the deal was announced. The acquisition is expected to close this year. Par had 2011 revenues of $926.1 million. Par rose $13.42 (37%) to $50 on Monday. ...